Cutaneous toxicity of antitumor therapy for hematologic malignancies: a literature review
https://doi.org/10.31549/2542-1174-2025-9-3-96-108
Abstract
This review presents the available data on possible variants of cutaneous toxicity of antitumor therapy for hematologic malignancies. The existing methods of prevention and treatment of manifestations of dermatological toxicity are described. Cutaneous lesions in patients with hematologic malignancies can be caused by a toxic-allergic reaction, chemotoxicity, and – in case of hematopoietic stem cell transplantation – by immune infl ammation. Adverse skin reactions can occur at diff erent stages of antitumor therapy. Each type of therapy has its own characteristics and manifestations of cutaneous toxicity. At the moment, it is impossible to completely avoid the occurrence of toxic dermatological reactions when using any type of therapy in oncohematology. In this regard, the key factor in improving the tolerance of antitumor treatment is timely adequate prevention and therapy of adverse toxic reactions.
About the Authors
R. V. German
Novosibirsk State Medical University
Russian Federation
Russian Federation
Regina V. German – Post-graduate Student, Senior Laboratory Assistant, Department of Dermatovenereology and Cosmetology
52, Krasny prosp., Novosibirsk, 630091
Т. B. Reshetnikova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Tatiana B. Reshetnikova – Dr. Sci. (Med.), Professor, Department of Dermatovenereology and Cosmetology
52, Krasny prosp., Novosibirsk, 630091
O. B. Nemchaninova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Olga B. Nemchaninova – Dr. Sci. (Med.), Professor, Head, Department of Dermatovenereology and Cosmetology
52, Krasny prosp., Novosibirsk, 630091
Е. N. Makhnovets
Novosibirsk State Medical University
Russian Federation
Russian Federation
Evgeniy N. Makhnovets – Cand. Sci. (Med.), Associate Professor, Department of Dermatovenereology and Cosmetology
52, Krasny prosp., Novosibirsk, 630091
References
1. Litvitsky P.F., Zhevak T.N. Hematological malignancies. Lymphocytic leukaemia. Current Pediatrics (Moscow). 2016;15(5):457-470. DOI: 10.15690/vsp.v15i5.1620. (In Russ.)
2. Shatochina E.A., Kruglova L.S., Kotenko K.V. Cutaneous toxicity of antineoplastic therapy and approaches to its correction. Russian Journal of the Physical Therapy, Balneotherapy and Reabilitation. 2016;15(4):185-187. DOI: 10.18821/1681-34562016-15-4-185-187. (In Russ.)
3. Potekaev N., Тrakhtman P., Rassokhina О. et al. Skin toxicity of chemotherapy and cutaneous manifestations of chronic graft versus host reaction. The principles of non-drug correction of skin lesions. Vrach. 2017;8:8-14. (In Russ.)
4. Koroleva I.A., Bolotina L.V., Gladkov O.A. et al. Recommendations for pharmaceutical treatment of dermatological reactions in patients receiving antitumor therapy. Malignant Tumors. Recommendations of the RUSSCO. 2021;113s2:99-113. (In Russ.)
5. Tkachenko E.V., Aravijskaya E.R., Gorbunova K.V. et al. (2019). Skin Toxicity as a Side Eff ect of Modern Antitumor Drugs: A Study Guide. St. Petersburg. P. 8–35. (In Russ.)
6. Kasparov B.S., Rogachev M.V., Belyaev A.M. et al. (2020). Outpatient Oncology. Practical Аspects: A Textbook. St. Petersburg. Pt. 2. P. 58–75. (In Russ.)
7. Borodavina E.V., Isaev P.A., Polkin V.V. et al. Cutaneous toxicity of the targeted therapy of malignant neoplasms. Problems in Oncology. 2022;68(5):539-547. DOI: 10.37469/0507-3758-2022-68-5-539-547. (In Russ.)
8. Michenko A.V., Kruglova L.S., Orlova K.V. et al. Itching and other manifestations of cutaneous toxicity in patients with melanoma on the background of therapy with BRAF and MEK inhibitors: a review of clinical guidelines on management tactics. Eff ective Pharmacotherapy. 2022;18(17):26-34. DOI: 10.33978/2307-3586-2022-18-17-26-34. (In Russ.)
9. Dermatological reactions during antitumor therapy: clinical guidelines/ Russian Society of Clinical Oncology. 2021. 45 p. URL: https://www.rosoncoweb.ru/standarts/projects/2021/dermatological_reactions. pdf (accessed 21.04.2025)
10. Shatokhina Е.А., Turkina А.G., Kruglova L.S. Dermatologic adverse events of Bcr-Abl tyrosine kinase inhibitors. Russian Journal of Hematology and Transfusiology. 2020;65(2):154-173. DOI: 10.35754/0234-5730-2020-65-2-154-173. (In Russ.)
11. Li Y., Ming Y., Fu R. et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front. Pharmacol. 2022;13:1-26. DOI: 10.3389/fphar.2022.950923.
12. Robak E., Jesionek-Kupnicka D., Robak T. Skin changes in hairy cell leukemia. Ann. Hematol. 2021;100(3):615- 625. DOI: 10.1007/s00277-020-04349-z.
13. Momin Z.K., Alame A., Vandergriff T. et al. Diff use purpuric eruption in a patient with acute myeloid leukemia. JAAD Case Rep. 2023;41:98-101. DOI: 10.1016/j.jdcr.2023.09.007.
14. Gaurav V., Lal A., Manandhar K. et al. Ara-C face: A malar rash. CosmoDerma. 2024;4:58. DOI: 10.25259/CSDM_47_2024.
15. Pospelova T.I., Skvortzova N.V., Nechunaeva I.N. Results of multiple myeloma treatment with Bortezomib. Oncohematology. 2009;4(2):35-41. DOI: 10.17650/1818-8346-2009-0-2-35-41. (In Russ.)
16. Valiev Т.Т. Mabthera (rituximab) in the treatment of prognostically unfavorable variants of B-cell lymphomas in children. Eff ective Pharmacotherapy. 2010;3:42-58. (In Russ.)
17. Morozova E., Teplyuk N., Grabovskaya O. et al. A case of polymorphic dermal angiitis in a B-cell chronic lymphocytic leukemia patient during rituximab therapy. Anti-Cancer Drugs. 2022;33(1):e776-e780. DOI: 10.1097/CAD.0000000000001193.
18. Malova М.D., Mikhailova S.N., Belysheva T.S. Highdosed Methotrexate in pediatric oncohematology: issues of toxicity of therapy. Bulletin of Hematology. 2023;19(3):22-27. (In Russ.)
19. Rumyantsev A.G., Maschan A.A. (2003). Pediatric Hematopoietic Stem Cell Transplantation: A Guide for Physicians. Мoscow. 909 p. (In Russ.)
20. Atkinson K., Champlin R., Ritz J. et al. (eds.) Clinical Bone Marrow and Blood Stem Cell Transplantation. UK: Cambridge university press, 2003. 2000 p.
21. Chubenko V.A. Complications of targeted therapy. Practical Oncology. 2010;11(3):192-202. (In Russ.)
22. Lacouture M.E., Sibaud V., Gerber P.A. et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann. Oncol. 2021;32(2):157-170. DOI: 10.1016/j.annonc.2020.11.005.
Review
For citations:
German R.V., Reshetnikova Т.B., Nemchaninova O.B., Makhnovets Е.N. Cutaneous toxicity of antitumor therapy for hematologic malignancies: a literature review. Journal of Siberian Medical Sciences. 2025;(3):96-108. (In Russ.) https://doi.org/10.31549/2542-1174-2025-9-3-96-108
Views:
10
Email this article 